Brief: Petros Pharmaceuticals Completes Pilot Label Comprehension Study
13/07/2021 14:17
July 13 (Reuters) - Petros Pharmaceuticals Inc PTPI.O :
* PETROS PHARMACEUTICALS COMPLETES PILOT LABEL COMPREHENSION
STUDY
TO INITIATE PROCESS FOR STENDRA® PRESCRIPTION ERECTILE
DYSFUNCTION MEDICATION TO ACHIEVE DESIGNATION AS AN
OVER-THE-COUNTER TREATMENT
Source text for Eikon: ID:nPn6vj6qza
Further company coverage: PTPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Petros Pharmaceuticals
See all newsBrief: Petros Pharmaceuticals Assigns All Assets To Pt Liquidation, For Benefit Of Creditors
Brief: Petros Pharmaceuticals’ STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Brief: Petros Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Petros Pharmaceuticals Expands Online Distribution For Prescription STENDRA(R) Through New Agreement With Lemonaid Health
Brief: Petros Pharma Announces Partnership with Idea Evolver for Rx-to-OTC Switches & Digital Launch Solutions